Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pitfalls in N-acetyltransferase 2 genotyping.

I Cascorbi1, I Roots

  • 1Institute of Clinical Pharmacology, University Clinic Charité, Humboldt University Berlin, Germany. ingolf.cascorbi@charite.de

Pharmacogenetics
|April 20, 1999
PubMed
Summary

Accurate arylamine N-acetyltransferase 2 (NAT2) genotyping requires careful attention to nomenclature and potential laboratory errors. Specific mutations are key for predicting acetylator phenotype, with additional checks needed for African populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activation of the cell membrane angiotensin AT2 receptors in human leiomyosarcoma cells induces differentiation and apoptosis by a PPARγ - dependent mechanism.

Neoplasma·2017
Same author

Epigenetics in Drug Response.

Clinical pharmacology and therapeutics·2016
Same author

Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?

Clinical pharmacology and therapeutics·2016
Same author

The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.

Gynecologic oncology·2016
Same author

Pharmacological treatment of pain: future trends and novel insights.

Clinical pharmacology and therapeutics·2015
Same author

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.

Cancer chemotherapy and pharmacology·2014

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Genetics

Background:

  • Increasing reports of diverse arylamine N-acetyltransferase 2 (NAT2) gene haplotypes present challenges in accurate genotyping.
  • Confusion arises from linking known hereditary point mutations to defined haplotypes and inconsistent nomenclature.
  • Existing methodologies and terminologies can lead to misinterpretation of NAT2 genotypes.

Purpose of the Study:

  • To address concerns regarding exact NAT2 genotyping and correct nomenclature.
  • To summarize common pitfalls in NAT2 genotyping methodologies and terminology.
  • To provide guidance on accurate interpretation of NAT2 alleles and phenotype prediction.

Main Methods:

  • Review and summarization of typical pitfalls in NAT2 genotyping methodologies.

Related Experiment Videos

  • Analysis of nomenclature issues in reporting NAT2 alleles and haplotypes.
  • Discussion of verification methods for novel NAT2 alleles, including subcloning.

    • Main Results:

    • Critical evaluation of NAT2 genotypes, especially those with rare alleles or combinations, is necessary to identify laboratory failures.
    • Verification of novel NAT2 alleles using subcloning or equivalent techniques is recommended.
    • Standard NAT2 mutations C282T and T341C are generally sufficient for acetylator phenotype prediction, except in African populations.

    Conclusions:

    • Accurate NAT2 genotyping demands rigorous methodology and consistent nomenclature to avoid errors.
    • The G191A mutation must be additionally genotyped in African populations for accurate slow acetylator phenotype prediction.
    • Adherence to best practices ensures reliable pharmacogenetic data for clinical and research applications.